Triple combo safe for children
A triple combination of antiretroviral drugs that includes nevirapine (Viramune) has been shown to be effective and safe in treating infants and children vertically infected with HIV.
A study published in the May 8 issue of the New England Journal of Medicine is the first to study a non-nucleoside reverse transcriptase inhibitor, such as nevirapine, in this population. The combination, which included zidovudine (AZT) and didanosine (ddI), suppressed HIV replication for more than six months in most of the children and infants studied.
All patients showed stable or increasing CD4 cells. No clinically significant adverse side effects were observed in the study.